FDA-approved drug may finally help immunotherapy defeat rare liver cancer
9d ago
Source
ScienceDailyFDA-approved drug may finally help immunotherapy defeat rare liver cancersciencedaily.comResearchers found that a rare liver cancer evades immunotherapy by luring immune T cells away from the tumor and trapping them in nearby fibrous tissue. An FDA-approved drug called AMD3100 freed those T cells to attack the cancer, significantly improving the effectiveness of immunotherapy in tumor samples.
You might also wanna read
Engineered immunotherapy drug eliminates aggressive metastatic cancers in clinical trial
Researchers at Rockefeller University have developed an engineered CD40 agonist antibody that successfully eliminated aggressive metastatic
rockefeller.edu·9mo ago
Study reveals how immunotherapy can drive immune evasion in pancreatic cancer through Treg cell activity and MHC-I suppression
This study investigates mechanisms driving immunotherapy resistance in pancreatic ductal adenocarcinoma (PDA). Using murine models, the rese
scim.ag·8d agoStudy reveals how immunotherapy can drive immune evasion in pancreatic cancer through Treg cell activity and MHC-I suppression
This study investigates mechanisms driving immunotherapy resistance in pancreatic ductal adenocarcinoma (PDA). Using murine models, the rese
scim.ag·4d ago
Johns Hopkins Study Finds Anti-Parasitic Drug Slows Pancreatic Cancer in Mice
Johns Hopkins Medicine researchers have discovered that an anti-parasitic drug can prevent the initiation, progression, and metastasis of pa
hopkinsmedicine.org·12d agoUS FDA approves AbbVie's rare blood cancer drug
reut.rs·1mo ago
Triple-action cancer jab amivantamab shrinks tumors in over a third of patients in international trial
An international trial across 11 countries shows that a triple-action cancer injection called amivantamab can shrink or completely eradicate
theguardian.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.